NCT00913393 - Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Type 2 Diabetes MellitusDiabetic NephropathyDiabetic Kidney Disease

Interventions

DRUG

FG-3019

3 mg/kg FG-3019 IV every 2 weeks for 22 weeks

DRUG

FG-3019

10 mg/kg FG-3019 IV every 2 weeks for 22 weeks

DRUG

Placebo

Placebo IV every 2 weeks for 22 weeks

Trial Locations (28)

Unknown

Tempe

Buena Park

Lakewood

Sacramento

Walnut Creek

Whittier

Atlanta

Evergreen Park

Topeka

Wichita

Kenner

Springfield

Saint Clair Shores

Lincoln

Omaha

Berlin

Buffalo

Flushing

New York

Greenville

Toledo

Chattanooga

Knoxville

Dallas

Houston

San Antonio

Fairfax

Spokane